Liposome-Based Silibinin for Mitigating Nonalcoholic Fatty Liver Disease: Dual Effects via Parenteral and Intestinal Routes.
Yan B, Zheng X, Wang Y, Yang J, Zhu X, Qiu M, Xia K, Wang Y, Li M, Li S, Ma X, Xie J, Li F, Fu T, Li W.
Yan B, et al. Among authors: fu t.
ACS Pharmacol Transl Sci. 2023 Nov 7;6(12):1909-1923. doi: 10.1021/acsptsci.3c00210. eCollection 2023 Dec 8.
ACS Pharmacol Transl Sci. 2023.
PMID: 38093834
Free PMC article.